Samsung Biologics will provide drug substance manufacturing and antibody development services for LegoChem Biosciences’ ADC candidate.
Under the terms of the agreement, contract manufacturing and development organization (CDMO) Samsung Biologics will develop and manufacture a portion of LegoChem’s antibody-drug conjugate (ADC) program to treat tumors. solid.
Although specific drug candidates have not been disclosed, LegoChem said it intends to submit an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) during of the first half of next year.
“We cannot disclose the financial terms of the latest partnership,” said a Samsung Biologics spokesperson. Introduced to bioprocesses. However, the spokesperson confirmed that “the services will be provided at Samsung Biologics’ biomanufacturing site in Songdo, South Korea.”
This latest ADC agreement follows CDMO’s statement that it is “on track” to complete construction of its ADC facility at Plant Five in the Songdo district of Incheon, South Korea.
“Samsung Biologics is set to complete construction of a dedicated, stand-alone ADC facility this year. We are investing in ADC as part of our ongoing efforts to expand our business portfolio and proactively respond to our customers’ needs and the dynamic market environment,” the spokesperson said.
In December 2022, Samsung Biologics announced plans to enter the ADC market in 2023. Since then, the company has made a series of investments in the ADC space through partnerships and its investment arm , the Samsung Life Science Fund. The fund is a joint creation of Samsung Biologics, Samsung C&T and Samsung Bioepis, managed by Samsung Ventures Investment Corporation (Samsung Ventures).
In September 2023, the company signed an ADC development pact with AimedBio after Samsung Ventures took an undisclosed stake in the company. The fund also invested in Araris Biotech to support the future advancement of potential ADC candidates in April 2023.
“We are committed to remaining at the forefront of advanced ADC technology by making strategic investments through the Samsung Life Science Fund,” the spokesperson told us.